刘玉 - 四川大学 - 生物治疗国家重点实验室

个人简介

中国抗癌协会血液肿瘤专业委员会髓系白血病学组委员，中国抗癌协会肿瘤营养与支持治疗专业委员会肿瘤代谢学组青年委员，四川省细胞生物学学会生物技术专委会主任委员。刘玉教授1997年毕业于北京师范大学获学士学位，2000年毕业于北京师范大学生物化学获硕士学位，2008年毕业于美国爱因斯坦医学院获得理学博士学位。2008-2014年先后在密歇根大学Dr. Pan Zheng/Dr.Yang Liu实验室、冷泉港实验室、纽约纪念斯隆凯特林癌症中心的Dr. Scott Lowe实验室从事研究工作。2014年受聘于四川大学华西医院/生物治疗国家重点实验室，任特聘研究员、血液肿瘤功能基因组研究室主任。

研究领域

1．血液肿瘤发生发展的分子机制及靶向治疗 2．造血干细胞的自我更新和分化机制 3．利用RNAi、CRISPR/Cas和动物模型等研究功能基因组学 3．CRISPR/Cas基因编辑构建基因工程小鼠

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Liu, Yu＃, Chen, C. ＃,Xu, Z.,Scuoppo, C., Rillahan, CD.,Gao,J., Spitzer, B., Bosbach, B., Kastenhubr, ER., Baslan, T., Ackermann, S., Cheng, L., Wang, Q., Niu, T., Schultz, N., Levine, RL., Mills, AA.& Lowe, SW., Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.2016, Nature,531:471-5.(#共同第一) 2. Ye, P.,＃Liu, Yu,＃ Chen, C., Tang F., Wu Q., Wang X., Liu, CG., Liu, X., Liu, Y.*& Zheng, P.*, An mTORC1-Mdm2-Drosha Axis for miRNA Biogenesis in Response to Glucose- and Amino Acid-Deprivation. 2015, Molecular Cell, 57(4):708-720. (#共同第一)（*共同通讯） 3. Liu, Yu& Chang, A., Heat shock response relieves ER stress. 2008, EMBO J. 27(7):1049-1059 4. Liu, Yu& Chang, A., A mutant plasma membrane protein is stabilized upon loss of Yvh1, a novel ribosome assembly factor. 2009, Genetics,181(3):907-915 5. Liu, Yu, Sitaraman, S., Chang, A., Multiple degradation pathways for misfolded mutants of the yeast plasma membrane ATPase, Pma1. 2006, J Biol Chem. 281(42):31457-31466 6. Liu, Yu, Chang, A., Quality control of a mutant plasma membrane ATPase: ubiquitylation prevents cell-surface stability. 2006, J Cell Sci. 119:360-369 7. Chen, C., Liu, Yu, Rappaport, AR., Kitzing, T., Schultz N., Zhao, Z., Shroff, AS., Dickins, R., Vakoc, Cr., Bradner, Je., Stock, W., LeBeau, MM., Shannon, KM.., Kogan, S., Zuber, J & Lowe, SW.MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. 2014, Cancer Cell, 25(5):652-665 8. Chen, C., Liu, Yu, Lu, C., Cross, JR., Morris JP 4th, Shroff AS, Ward PS, Bradner JE, Thompson C & Lowe SW. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. 2013, Genes Dev., 27(18):1974-1985 9. Chen, C., Liu, Yu, Liu,Y.* & Zheng, P.*, Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice. 2010, J Clin Invest, 120(11): 4091-4101（*共同通讯） 10.Chen, C., Liu, Yu, Liu,Y.* & Zheng, P.*, mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. 2009, Sci Signal, 2(98):ra75 1-7（*共同通讯） 11.Chen, C., Liu, Yu, Liu, R., Ikenoue, T., Guan, KL., Liu, Y.* & Zheng, P.*, TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. 2008, J Exp Med., 205:2397-2408（*共同通讯） 12.Wu, Q., Liu, Yu, Chen, C., Ikenoue, T., Qiao, Y., Li, CS., Li, W., Guan, KL., Liu, Y.*, & Zheng, P.*, The Tuberous Sclerosis Complex-Mammalian Target of Rapamycin Pathway Maintains the Quiescence and Survival of Naive T Cells. 2011, J Immunol., 187(3):1106-1112（*共同通讯） 13.Chen, C., Liu, Yu, Liu, Y.* & Zheng, P.*, The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells. 2009, Cell Cycle, 8:1158-1160（*共同通讯） 14.Han, S., Liu, Yu& Chang, A., Cytoplasmic Hsp70 promotes ubiquitination for ER-associated degradation of a misfolded mutant of the yeast plasma membrane ATPase, PMA1. 2007, J Biol Chem. 282:26140-26149